Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer.

Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer.

Publication date: Jun 26, 2024

In patients with lung cancer (LC), understanding factors that impact the dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike antibody (SAb) titers over time is critical, but challenging, due to evolving treatments, infections, vaccinations, and health status. The objective was to develop a time-dependent regression model elucidating individual contributions of factors influencing SAb levels in LC patients using a prospective, longitudinal, multi-institutional cohort study initiated in January 2021. The study evaluated 296 LC patients-median age 69; 55% female; 50% stage IV. Blood samples were collected every three months to measure SAb levels using FDA-approved ELISA. Asymptomatic and unreported infections were documented through measurement of anti-nucleocapsid Ab levels (Meso Scale Discovery). Associations between clinical characteristics and titers were evaluated using a time-dependent linear regression model with a generalized estimating equation (GEE), considering time-independent variables (age, sex, ethnicity, smoking history, histology, and stage) and time-dependent variables (booster vaccinations, SARS-CoV-2 infections, cancer treatment, steroid use, and influenza vaccination). Significant time-dependent effects increasing titer levels were observed for prior SARS-CoV-2 infection (p < 0. 001) and vaccination/boosters (p < 0. 001). Steroid use (p = 0. 043) and chemotherapy (p = 0. 033) reduced titer levels. Influenza vaccination was associated with increased SAb levels (p < 0. 001), independent of SARS-CoV-2 vaccine boosters. Prior smoking significantly decreased titers in females (p = 0. 001). Age showed no association with titers. This GEE-based linear regression model unveiled the nuanced impact of multiple variables on patient anti-spike Ab levels over time. After controlling for the major influences of vaccine and SARS-CoV-2 infections, chemotherapy and steroid use were found to have negatively affected titers. Smoking in females significantly decreased titers. Surprisingly, influenza vaccinations were also significantly associated, likely indirectly, with improved SARS-CoV-2 titers.

Open Access PDF

Concepts Keywords
Cancer lung cancer therapies
Influenza SARS-CoV-2 antibody levels
Stage time-dependent regression model
Vaccinations

Semantics

Type Source Name
disease VO time
disease MESH Lung Cancer
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH infections
disease IDO blood
disease IDO history
disease MESH SARS-CoV-2 infections
disease MESH cancer
disease MESH influenza
disease VO vaccination
disease VO titer
pathway REACTOME SARS-CoV-2 Infection
disease VO vaccine
disease VO age
disease VO USA
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH complications
disease MESH death
disease MESH hypertension
disease MESH seroconversion
disease VO population
disease IDO immune response
disease VO antibody titer
disease MESH morbidities
disease VO vaccinated
disease VO dose
disease MESH Adenocarcinoma
disease MESH Squamous Carcinoma
drug DRUGBANK Edetic Acid
disease IDO assay
disease VO Ad26.COV2.S
drug DRUGBANK Trestolone
disease IDO infection
disease VO frequency
drug DRUGBANK Prednisone
drug DRUGBANK Methylprednisolone
drug DRUGBANK Dexamethasone
drug DRUGBANK Hydrocortisone
drug DRUGBANK Platinum
drug DRUGBANK Pemetrexed
drug DRUGBANK Gemcitabine
drug DRUGBANK Vinorelbine
drug DRUGBANK Osimertinib
drug DRUGBANK Erlotinib
drug DRUGBANK Gefitinib
drug DRUGBANK Afatinib
drug DRUGBANK Dacomitinib
drug DRUGBANK Bevacizumab
drug DRUGBANK Ramucirumab
drug DRUGBANK Crizotinib
drug DRUGBANK Alectinib
drug DRUGBANK Brigatinib
drug DRUGBANK Ceritinib
drug DRUGBANK Lorlatinib
drug DRUGBANK Entrectinib
drug DRUGBANK Capmatinib
drug DRUGBANK Larotrectinib
drug DRUGBANK Cabozantinib
drug DRUGBANK Vandetanib
drug DRUGBANK Pembrolizumab
drug DRUGBANK Nivolumab
drug DRUGBANK Atezolizumab
drug DRUGBANK Durvalumab
drug DRUGBANK Cemiplimab
drug DRUGBANK Ipilimumab
disease IDO intervention

Original Article

(Visited 1 times, 1 visits today)